MIM
MIRM icon

MetLife Investment Management’s Mirum Pharmaceuticals MIRM Stock Holding History

MetLife Investment Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.23M Buy
27,621
+4,798
+21% +$482K 0.01% 875
2026
Q1 		$2.11M Buy
22,823
+84
+0.4% +$7.9K 0.01% 1029
2025
Q4 		$1.8M Sell
22,739
-735
-3% -$52.8K 0.01% 1133
2025
Q3 		$1.72M Sell
23,474
-2,473
-10% -$157K 0.01% 1159
2025
Q2 		$1.32M Buy
25,947
+2,223
+9% +$99K 0.01% 1175
2025
Q1 		$1.07M Sell
23,724
-361
-1% -$17K 0.01% 1335
2024
Q4 		$996K Buy
24,085
+1,356
+6% +$56.5K 0.01% 1415
2024
Q3 		$886K Hold
22,729
– – 0.01% 1459
2024
Q2 		$777K Buy
22,729
+8,604
+61% +$226K ﹤0.01% 1488
2024
Q1 		$355K Sell
14,125
-32,628
-70% -$897K ﹤0.01% 1869
2023
Q4 		$1.38M Buy
46,753
+32,628
+231% +$987K 0.01% 1134
2023
Q3 		$446K Hold
14,125
– – ﹤0.01% 1706
2023
Q2 		$365K Buy
14,125
+5,183
+58% +$138K ﹤0.01% 1897
2023
Q1 		$215K Buy
8,942
+514
+6% +$11.7K ﹤0.01% 2175
2022
Q4 		$164K Hold
8,428
– – ﹤0.01% 2369
2022
Q3 		$177K Hold
8,428
– – ﹤0.01% 2374
2022
Q2 		$164K Buy
+8,428
New +$199K ﹤0.01% 2446

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MetLife Investment Management's MIRM Position: Q2 2026 in Review

MetLife Investment Management increased its Mirum Pharmaceuticals (MIRM) stake by 21% in Q2 2026, buying an estimated $482K and bringing the position to 27,621 shares worth $3.23M. The position accounts for 0.01% of the portfolio, ranked #875.

MetLife Investment Management first reported a position in MIRM in Q2 2022 and has held it in 17 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • MetLife Investment Management held 27,621 shares of Mirum Pharmaceuticals worth $3.23M as of Q2 2026.
  • MetLife Investment Management bought 4,798 Mirum Pharmaceuticals shares in Q2 2026, an estimated $482K.
  • Mirum Pharmaceuticals made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #875 holding.
  • MetLife Investment Management first reported a position in Mirum Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.